Tivicay (dolutegravir recalls
The FDA has published 2 recalls involving Tivicay (dolutegravir since 2014. The latest was reported on 1 Jun 2022. GlaxoSmithKline has the most recalls in this group. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.
Total recalls2since 2014
Last 12 months0reported
Class I00% of total
Ongoing0latest 1 Jun 2022
Recalls per month, last 24 months
click a bar for that monthSeverity split
Class I 0 0%Class II 0 0%Class III 2 100%
Why tivicay (dolutegravir is recalled
Companies
By year
All tivicay (dolutegravir recalls, newest first
2 total| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS III | Tivicay (dolutegravir) Tablets 50 mg recalled by GlaxoSmithKline | GlaxoSmithKline | Other | Nationwide |
| Drug | CLASS III | Tivicay (dolutegravir) Tablets 50 mg recalled by Viiv Healthcare | Viiv Healthcare | Other | Nationwide |
Should you stop taking Tivicay (dolutegravir?
Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.